Ekso Bionics Holdings Statistics

Total Valuation

Ekso Bionics Holdings has a market cap or net worth of GBP 11.48 million. The enterprise value is 9.90 million.

Market Cap	11.48M
Enterprise Value	9.90M

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+29.99%
Shares Change (QoQ)	+11.45%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	17.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	1.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.19
EV / Sales	0.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.32

Financial Position

The company has a current ratio of 2.81, with a Debt / Equity ratio of 0.43.

Current Ratio	2.81
Quick Ratio	2.03
Debt / Equity	0.43
Debt / EBITDA	n/a
Debt / FCF	-0.63
Interest Coverage	-42.32

Financial Efficiency

Return on equity (ROE) is -73.89% and return on invested capital (ROIC) is -33.21%.

Return on Equity (ROE)	-73.89%
Return on Assets (ROA)	-24.17%
Return on Capital (ROIC)	-33.21%
Revenue Per Employee	185,810
Profits Per Employee	-116,970
Employee Count	72
Asset Turnover	0.59
Inventory Turnover	1.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.75% in the last 52 weeks. The beta is 1.88, so Ekso Bionics Holdings's price volatility has been higher than the market average.

Beta (5Y)	1.88
52-Week Price Change	-70.75%
50-Day Moving Average	0.83
200-Day Moving Average	1.31
Relative Strength Index (RSI)	40.35
Average Volume (20 Days)	35,519

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.23

Income Statement

In the last 12 months, Ekso Bionics Holdings had revenue of GBP 13.19 million and -8.30 million in losses. Loss per share was -0.47.

Revenue	13.19M
Gross Profit	6.84M
Operating Income	-8.71M
Pretax Income	-8.30M
Net Income	-8.30M
EBITDA	-7.49M
EBIT	-8.71M
Loss Per Share	-0.47

Full Income Statement

Balance Sheet

The company has 6.19 million in cash and 4.73 million in debt, giving a net cash position of 1.45 million.

Cash & Cash Equivalents	6.19M
Total Debt	4.73M
Net Cash	1.45M
Net Cash Per Share	n/a
Equity (Book Value)	11.09M
Book Value Per Share	0.50
Working Capital	10.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.46 million and capital expenditures -44,020, giving a free cash flow of -7.50 million.

Operating Cash Flow	-7.46M
Capital Expenditures	-44,020
Free Cash Flow	-7.50M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 51.84%, with operating and profit margins of -66.05% and -62.95%.

Gross Margin	51.84%
Operating Margin	-66.05%
Pretax Margin	-62.95%
Profit Margin	-62.95%
EBITDA Margin	-56.76%
EBIT Margin	-66.05%
FCF Margin	n/a

Dividends & Yields

Ekso Bionics Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.99%
Shareholder Yield	-29.99%
Earnings Yield	-72.31%
FCF Yield	-65.33%

Stock Splits

The last stock split was on March 25, 2020. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	Mar 25, 2020
Split Type	Reverse
Split Ratio	0.0666666667

Scores

Ekso Bionics Holdings has an Altman Z-Score of -11. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11
Piotroski F-Score	n/a